Ligand Pharmaceuticals Acquires XOMA Royalty for $39/Share, Raises 2026 Guidance
Ligand Pharmaceuticals has agreed to acquire XOMA Royalty for $39 per share in cash plus a contingent value right tied to TREMFYA litigation. The deal is expected to close in Q3 2026 and is projected to be immediately accretive to earnings. Ligand has raised its 2026 guidance for royalty revenue, total revenue, and adjusted EPS.
Topics: acquisition contingent value right EPS outlook financial guidance royalty portfolio